Tredje AP fonden Has $1.38 Million Position in Hologic, Inc. (NASDAQ:HOLX)

Tredje AP fonden trimmed its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 50.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 19,096 shares of the medical equipment provider's stock after selling 19,095 shares during the period. Tredje AP fonden's holdings in Hologic were worth $1,377,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. State Street Corp lifted its position in Hologic by 0.8% in the 3rd quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider's stock valued at $847,944,000 after purchasing an additional 81,057 shares during the last quarter. FMR LLC lifted its position in Hologic by 64.0% in the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider's stock valued at $453,940,000 after purchasing an additional 2,174,093 shares during the last quarter. Victory Capital Management Inc. lifted its position in Hologic by 0.5% in the 4th quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider's stock valued at $354,506,000 after purchasing an additional 24,358 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Hologic by 0.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider's stock valued at $208,051,000 after purchasing an additional 18,774 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in Hologic by 8.6% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider's stock valued at $200,952,000 after purchasing an additional 195,285 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Several analysts recently weighed in on HOLX shares. Wolfe Research assumed coverage on shares of Hologic in a research report on Friday, December 13th. They issued a "peer perform" rating on the stock. Royal Bank of Canada lowered their target price on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a research note on Thursday, February 6th. Stephens reissued an "overweight" rating and set a $84.00 target price on shares of Hologic in a research note on Thursday, February 6th. Evercore ISI lowered their target price on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a research note on Thursday, February 6th. Finally, Needham & Company LLC cut shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 target price on the stock. in a research note on Monday, February 3rd. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $84.62.

Hologic Price Performance

Shares of HOLX traded down $0.51 during mid-day trading on Wednesday, hitting $61.47. The company's stock had a trading volume of 3,261,413 shares, compared to its average volume of 2,418,794. Hologic, Inc. has a fifty-two week low of $60.33 and a fifty-two week high of $84.67. The firm has a 50-day moving average price of $66.72 and a 200 day moving average price of $74.37. The stock has a market capitalization of $13.79 billion, a price-to-earnings ratio of 19.39, a PEG ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.